Core Insights - New findings indicate that Telomir-1 significantly impacts CASP8 and GSTP1, which are essential genes involved in regulating cell death and detoxification pathways often altered in cancer [1] Company Summary - Telomir Pharmaceuticals, Inc. is a pre-clinical biotechnology company focused on developing therapies that address the epigenetic causes of cancer, aging, and age-related diseases [1] - The company reported new preclinical data from an in vivo study involving mice with human aggressive prostate cancer tumors [1] Research Findings - The study evaluated DNA-methylation changes in the defense genes CASP8 and GSTP1 after treatment with oral Telomir-1, Rapamycin, chemotherapy, and combination regimens [1]

Summary of Longevity Industry Insights Industry Overview - The longevity market is a multi-billion dollar industry, encompassing high-tech diagnostics, gene modulation, anti-aging medications, and lifestyle apps aimed at extending healthy life spans [14][20][94] - The global revenue from longevity products is projected to grow from $20 billion to over $60 billion by 2035, indicating a significant market opportunity [97] Key Insights - **Market Drivers**: The longevity movement is driven by research institutions, investors, and consumers seeking healthier aging solutions. Notable tech billionaires like Jeff Bezos and Peter Thiel are heavily investing in this sector [97][94] - **Research and Development**: Institutions like the Cologne Excellence Cluster for Aging and Aging-Associated Diseases (CECAD) are at the forefront of aging research, focusing on understanding the biological mechanisms of aging and developing preventive measures [96][102] - **Innovative Approaches**: Promising research includes the use of drugs like Rapamycin and Metformin, which have shown potential in extending lifespan in animal studies [123][124] - **Start-up Landscape**: Numerous start-ups are emerging in the longevity space, such as Refoxy Pharma, which focuses on the FOXO3 gene to combat age-related diseases [126][130] Emerging Trends - **Cultural Shift**: There is a growing belief that aging is not an inevitable decline but a process that can be managed and potentially reversed through scientific advancements [95][101] - **Investment in Longevity**: Venture capital firms like Apollo Health Ventures and Kizoo Technology Capital are actively funding longevity research and start-ups, indicating strong financial backing for innovative solutions [135] - **Skepticism and Caution**: Despite the hype, many products marketed as longevity solutions lack scientific validation. Experts caution consumers to be wary of unproven claims, especially in the cosmetic and supplement sectors [142][121] Noteworthy Developments - **Conferences and Collaborations**: Events like the Zuzalu conference in Montenegro bring together global leaders in the longevity movement to discuss innovative approaches and potential collaborations [94][95] - **Regulatory Challenges**: Obtaining regulatory approval for preventive medications remains a significant hurdle, as current frameworks primarily support treatments for existing conditions rather than preventive measures [130] Conclusion - The longevity industry is rapidly evolving, with significant investments and research efforts aimed at extending healthy life spans. However, consumers should approach marketed solutions with caution, as many claims are not yet substantiated by rigorous scientific evidence. The future of this industry will likely depend on successful research outcomes and the ability to translate findings into practical applications.

Both rapamycin and metformin have drawn the attention of the “live for ever” brigade. But what does the science say about their effectiveness? https://t.co/FfnxuNij4GIllustration: Cristina Spanò https://t.co/pE6psv9Mbi ...